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Introduction
Type2 Diabetes Mellitus (T2DM) as a chronic disease, is 
on rise in parallel with other non-communicable 
diseases, not only in adults but also in children and 
adolescents worldwide.1 190 million people were 
diabetic in 2008 and according to estimates this number 
will reach 366 million in 2030.2 Both host genetics and 
environmental factors are clearly associated with the 
onset of T2DM.3 Epidemiological studies revealed that 
there is a positive relation between high blood glucose 
levels (glycemia), lipid abnormalities and cardiovascular 
diseases.4  
Beyond the generally acknowledged idea that genetic 
factors assume an imperative part in diabetes 
susceptibility, developing evidence has shown that some 
variables such as chemical and diet, can affect diabetes 
development. Increasing evidence indicates that gut 
microbiota is strongly associated with type2 diabetes 
development.5  
As compared to non-diabetic subjects, diabetic subjects 
experienced a decrease in butyrate-producing bacteria 
such as Roseburia intestinalis and increases in 
Lactobacillus gasseri and some Clostridium 
microorganisms. Moreover, increased expression of 
microbiota genes involved in oxidative stress and 
inflammation was observed in diabetic patients.6  
Probiotics, prebiotics and synbiotics may alter the gut 
microbiota and stabilize microbial communities. 
Probiotics are defined as live microorganisms that 
can exert health effects on the host when 
administered adequately and were first described by 
Metchinkoff in 1908.3,7 Probiotics have a pivotal role 
in the host’s general health.3 These products can be 
used as anti-diabetic agents since various studies have 
shown their possible ability to improve glucose 
homeostasis and delay the progression of diabetes in 
animal models.8-11  
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Abstract 
Purpose: Diabetes Mellitus (T2DM) as a chronic disease, is on rise in parallel with other 
non-communicable diseases. Several studies have shown that probiotics and prebiotics 
might exert beneficial effects in chronic diseases including diabetes. Because of 
controversial results from different trials, the present study aims to assess the effects of 
prebiotic/synbiotic consumption on metabolic parameters in patients with type2 diabetes.  
Methods: A systematic literature search was performed on randomized controlled trial 
published in PubMed/Medline, SciVerse Scopus, Google scholar, SID and Magiran up to 
March 2018. Of a total number of 255 studies found in initial literature search, ten 
randomized controlled trials were included in the meta-analysis. The pooled mean net 
change were calculated in fasting blood-glucose [FBG], Hemoglobin A1c [HbA1c] and 
lipid markers (total cholesterol [TC], triglyceride [TG], low-density lipoprotein cholesterol 
[LDL-C], high density lipoprotein cholesterol [HDL-C]). The meta-analyses was conducted 
using Revman Software (v5.3). 
Results: The pooled estimate indicated a significant difference for the mean change in FBG, 
HbA1c and HDL in treatment group in comparison with control group. Subgroup analysis 
by intervention showed a significant difference in TG, LDL and HDL (synbiotic group) and 
in TG, TC, FBG, HDL and HbA1c (prebiotic group) compared with placebo. In another 
subgroup analysis, high quality studies showed significant reductions in TG, TC, FBG and 
HbA1c in intervention group compared with placebo group.  
Conclusion: In summary, diets supplemented with either prebiotics or synbiotics can result 
in improvements in lipid metabolism and glucose homeostasis in type 2 diabetic patients.  
Review Article 
  566  | Advanced Pharmaceutical Bulletin, 2018, 8(4), 565-574 
Mahboobi et al. 
A prebiotic is non-digestible food component that 
selectively stimulates the activity or growth of a few 
number of probiotic bacteria in the colon, especially, but 
not exclusively, lactobacilli and bifidobacteria.12 
Manipulation of gut microbiota through prebiotic 
consumption can exert metabolic health benefits in high 
risk individuals.13 
Synbiotic is a combination of probiotics and prebiotics 
which promotes host’s metabolic health by selective 
growth stimulation and healthy microorganism 
activation. Synbiotic is a compound beyond a mixture of 
probiotics and prebiotics but there is a synergistic effects 
of these two components that makes it a more effective 
supplement compared with probiotic or prebiotic 
separately.14  
Several studies suggest positive effects of synbiotics on 
blood lipid profile,4,15,16 while some other studies have 
failed to prove the positive effects of probiotics, as a part 
of synbiotics, on cholesterol.17,18 Furthermore, it has been 
observed that synbiotics might promote fasting blood 
glucose (FBG), insulin levels, and the homeostasis model 
assessment-insulin resistance (HOMA-IR).15 
RCTs evaluating effects of prebiotics alone or in 
combination with probiotics have yielded controversial 
results. Therefore, there is a need for a study to provide a 
comprehensive conclusion on the effects of 
prebiotic/synbiotic supplementation in diabetic patients. 
The present study aims to evaluate whether 
prebiotic/synbiotic consumption can beneficially affect 
metabolic parameters including glycemic status and lipid 
profile in patients with type 2 diabetes in compared with 
non-diabetic subjects.  
 
Materials and Methods 
The current meta-analysis was undertaken in accordance 
with Preferred Reporting Items for Systematic reviews 
and Meta-Analyses(PRISMA) statement for systematic 
review and interventional researches.19 
 
Data Sources and Search Strategies 
Systematic research was conducted on the following 
electronic databases: PubMed/Medline®, SciVerse 
Scopus®, Google scholar, SID® and Magiran®; in order 
to detect the medical literatures for Randomized 
Controlled Trials (RCTs) of the effects of synbiotic and 
prebiotic supplementation on lipid profile and glycaemia 
in patients with DM. These databases were searched up 
to March 2018. Moreover, the keywords were applied 
included: (prebiotic OR synbiotic OR symbiotic OR 
fructooligosaccharide OR fructo-oligosaccharide OR 
galactooligosaccharide OR galacto-oligosaccharide OR 
inulin OR lactulose OR FOS OR GOS OR oligofructose) 
and (cholesterol OR “plasma lipids” OR triglycerides OR 
TG OR HDL-c OR LDL-c OR “serum lipids” OR FBS 
OR FBG OR “fasting blood glucose” OR HbA1c). 
The search strategy was implemented based on the 
database orientations using Boolean operators (OR and 
AND), parenthesis and quotation marks. Quotation marks 
were used to search for exact terms or expressions; 
parenthesis was used for representing a group of search 
words or combination of two categories of search words to 
capacitate all probable combinations of statements. 
  
Study Selection 
Studies must have had these following inclusion criteria 
to enter this meta-analysis: a controlled clinical trial in 
humans, that included synbiotic or prebiotic supplement 
intervention, in forms of either supplement or enriched 
food, and evaluated at least one of the following 
outcomes: TG,TC, LDL-c, HDL-c, FBG and HbA1c. In 
addition, only the human RCTs published in English or 
Persian language were used in the meta-analysis, 
whereas animal/molecular, observational, preclinical and 
duplicate studies, commentaries, case reports or series, 
conference proceedings, editorials, and book 
chapters/reviews were excluded. 
 
Data Extraction and Quality Assessment 
Data were extracted from qualified papers by two 
independent authors (F.R and S.M) using predefined 
protocols and cross-checked. Any divergence of opinion 
was resolved by consulting a third reviewer (S.J). The 
following data were extracted from the selected articles: 
year of publication, region (country), sample size, age, 
sex, follow-up duration, design of study, distinguishing 
the type of consumed supplement (prebiotic, synbiotic or 
placebo), dose of consumed synbiotic and prebiotic, 
methods of synbiotic/prebiotic delivery, clinical 
condition, and mean changes of metabolic indices. All 
the above-mentioned data were arranged in the Microsoft 
Office Excel® 2013 document (Microsoft Corporation, 
Washington, USA).  
The Jadad Scale was computed to assess the 
methodological quality of included clinical trial studies. 
Jadad Scores range from 0(very low) to 5(very high) 
based on 3 distinct parts of randomization, double 
blinding, and follow-up. This scale assigns 1 point for 
mentioning randomization in the text, 1 point for 
mentioning blinding in the text, 1 point for proper 
description of the fate of all subjects. 1 point if the 
randomization method was appropriate (−1 if 
inappropriate) and 1 point if the double-blinding was 
appropriate (−1 if inappropriate).20  
 
Quantitative data synthesis 
The meta-analyses was conducted using Review 
Manager Software (Version 5.3; Oxford, England). 
Furthermore, metabolic factors alterations from the 
baseline to the final time point of RCTs were calculated 
as the Mean Differences (MD) with the 95% Confidence 
Interval (CIs). 
All values were collated as in mg/dL and mmol/L. Mean 
net changes and standard deviation in metabolic indices 
including TC, TG, LDL-c, HDL-c, HbA1C and FBG 
were calculated for all studies. The conversion factor for 
cholesterol (consist of HDL-c, LDL-c and TC), TG and 
FBG was 1 mmol/L=38.66 mg/dL, 1 mmol/L=88.57 
mg/dL and 1 mmol/dL=18 mg/dL; respectively. 
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For assessment the degree of inconsistency across studies 
by heterogeneity, the I2 statistic was used and either fixed 
or random effects models were used according to the 
findings. An I2 value of larger than 50% reflects moderate 
to high heterogeneity. To clarify the influence of studies 
characteristics, pre-specified subgroup analyses were 
conducted based on the Cochrane handbook. We assessed 
the publication bias by visual inspection of funnel 
plots test. Asymmetric shape of funnel-plot can be 
indicative of a publication bias. Moreover, Egger’s 
weighted regression test and Begg’s rank correlation test 
were used to examine possible bias. A P-value of less than 
0.05 was considered as statistically significant. 
 
Results and Discussion 
Study selection 
A flow chart of literature search and selection is 
presented in Figure 1. In our initial search, 255 
potentially relevant articles were identified. Of these, 8 
were excluded because they were review articles. 15 
were excluded because they were not available in either 
English or Persian language. Moreover, one-hundred 
forty six studies were excluded after screening the titles 
and summaries due to irrelevance and fifty-six 
potentially eligible articles were left for full-text 
assessing. Out of the 56 studies, 46 were excluded 
because they were preclinical studies or with lacking 
characterization of the subjects, with inadequate 
reporting of data, with insufficient data of placebo 
groups or with outcome measures other than lipid and 
glycemic indices. Finally a total of 10 RCTs were 
included in the present mete-analysis (Figure 1).  
 
 
Figure 1. Meta-analysis Flow Diagram 
Study characteristics/quality assessment 
Table 1 shows characteristics of the included studies. 
These studies were all RCTs published up to March 
2018. A total of 506 participants (including 251 subjects 
in the intervention group and 255 subjects in the control 
group) were reanalyzed in this study. The age of 
participants in trials varied from 20 to 70 years. Duration 
of intervention varied from 4 to 12 weeks. Four 
studies4,15,16,21 used the synbiotic and six studies22-27 used 
the prebiotic as intervention. Based on several previous 
meta-analysis studies which indicated the studies with 
Jadad score of more than 3 as high quality studies,28-30 
seven studies were classified as high quality studies16,21-
25,27 and the remaining three4,15,26 as low quality studies.  
The present systematic review and meta-analysis 
summarizes data from 10 RCTs including a total number 
of 506 participants. Our finding supports the idea that 
prebiotic supplementation may improve some factors of 
blood lipids and glycemic control in type2 diabetic 
patients. In general, the findings are consistent with 
results of most individual studies; of 10 included studies, 
8 reported some beneficial effects of prebiotic/synbiotics 
on glycaemia and lipid profile.4,15,16,22-24,27,31 In recent 
years, a considerable number of researches have been 
conducted with a focus on probable beneficial effects of 
prebiotics or synbiotics on metabolic profile in different 
target groups. There are limited systematic reviews 
which investigate the effects of synbiotic and/or prebiotic 
supplements on metabolic parameters in diabetic and/or 
overweight subjects. However, lack of subgroup analyses 
is considered as their limitation.32,33 Therefore, our study 
is the first comprehensive meta-analysis, evaluating 
whether synbiotic/prebiotic supplementation has 
favorable effects on metabolic indices on diabetic 
patients based on both intervention and study quality 
analyses. 
 
The effects of intervention on blood glucose and lipid 
concentration 
Since there were different units for applied indices in 
included trials, they were transformed to single unit 
(mg/dl) for TG, TC, LDL-c, HDL-c and FBG. As there 
were significant heterogeneity among studies for the 
mean change of most indicators (except for HDL-c), the 
random effects model was used for pooling data.  
The pooled mean net change for TG in treatment group 
was -29.75 compared with control group that was 
statistically significant [95%CI: -54.51, -4.98; p for 
heterogeneity < 0.00001, I2=93%]. For serum total 
cholesterol level, the pooled mean net change was -10.98 
in treatment group [95%CI: -25.48, 3.51; p for 
heterogeneity < 0.00001, I2=86%] that did not differ 
significantly compared with control group. Included 
studies investigated effects of prebiotic supplementation 
on LDL-c levels. There was a marginally significant 
difference between pooled mean net change for treatment 
group compared with placebo group, considering this 
marker [WMD -8.87, 95%CI: -18.63, 0.88; p for 
heterogeneity < 0.00001, I2=84%]. Intervention group 
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showed a significant rise in HDL-c compared with 
control group [WMD 4.89, 95%CI: 4.14, 5.63; p for 
heterogeneity =0.06, I2=47%] (Figure 2).  
Serum levels of FBG were measured in all included 
trials. The pooled estimate indicated a significant 
difference for the mean change in both FBG and HbA1c 
in treatment group in comparison with control group 
[FBG WMD -11.74, 95%CI: -23.04, -0.44; p for 
heterogeneity < 0.00001, I2=98%]. Mean change for 
HbA1c was calculated in six included studies. Total 
mean difference for HbA1c was -0.49 [95%CI: -0.77, -
0.21; p for heterogeneity < 0.00001, I2=91%] (Figure 2). 
 
Publication bias 
The funnel plot test was conducted to evaluate potential 
publication bias of the present meta-analysis. In the 
present meta-analysis, we assessed the publication bias 
by examining funnel plot test of the effects of 
prebiotic/synbiotic on HDL and LDL. Symmetrical 
funnel plots suggested that there is no publication bias 
(Figure 3). The absence of publication bias was 
conﬁrmed by Egger’s linear regression of LDL 
(intercept: 1.5; standard error: 529; 95% CI: -11.4, 14.4; 
t= 0.28, df=6; two-tailed p= 0.78). Additionally, 
publication bias was not apparent by Begg’s rank 
correlation test (Kendall’s Tau with continuity 
correction: 0.03; z=0.12; two-tailed p= 0.9).  
 
Table 1. Characteristics of included trials 
Auther Journal Year Country 
No. of 
Subjects 
in case 
group 
No. of 
controls 
Gender 
Age 
(years) 
Clinical 
Condition 
of 
Subjects 
Follow-
up 
Duration 
Prebiotic or 
Synbiotic 
compounds 
Dosage 
Significant 
Outcome 
Jadad 
score 
Asemi et al. 
Clinical 
Nutrition 
2014 Iran 31 31 F/M 35-70 T2DM 
6 
weeks 
Synbiotic 
Lactobacillus sporogenes 
(1 107 CFU), 
0.04 g inulin (HPX) as 
prebiotic with 0.38 g 
isomalt, 0.36 g sorbitol 
and 0.05 g stevia as 
sweetener per 1 g, three 
times a day in a 9 g 
package 
Reduction in 
serum insulin, 
FPG, triglyceride 
and hs-CRP; 
increase in HDL-
C, total GSH and 
uric acid 
3 
Bonsu et al. 
Int J 
Diabetes & 
Metab 
2012 Canada 12 14 F/M >40 T2DM 
12 
weeks 
Prebiotic 
10 g of inulin-based 
fiber/pelacpo:xylitol 
No significant 
outcome 
5 
Dehghan et 
al. 
Compleme
ntary 
Therapies 
in Medicine 
2016 Iran 27 22 F 30-65 T2DM 
2 
months 
Prebiotic 
10 g of oligofructose-
enriched inulin 
Reduction in 
BMI,WC, HC, 
DBP, fasting 
serum glucose, 
HbA1c, serum 
lipids, IL-12, IFN-
ϒ; increase in IL-
4 
5 
Dehghan et 
al. 
Int J Food 
Sci Nutr 
2013 Iran 24 25 F 20-65 T2DM 
8 
weeks 
Prebiotic 
10g/d inulin/10g/d 
maltodextrin(placebo) 
Reduction in 
FBS, HbA1c, total 
cholesterol, TG, 
LDL-C, LDL-
C/HDL-C ratio, 
TC/HDL-C ratio; 
increase in HDL-c 
5 
Ebrahimi et 
al. 
J diabetes 
metabolic 
disorders 
2017 Iran 35 35 F M 
58(aver
age) 
T2DM 
9 
weeks 
Synbiotic 
500 mg/day 
Streptococus 
thermophilus, Fructo 
oligosaccharide, 0.5 mg 
lactose 
Improve the 
HbA1c, BMI 
and 
Microalbuminuri
a 
4 
Luo et al. 
Human 
Nutrition 
and 
Metabolis
m 
2000 France 10 10 F/M 
57(aver
age) 
T2DM 
4 
weeks 
Prebiotic 
20 g/d Short-chain 
fructooligosaccharides 
(FOS)/ sucrose(placebo) 
No significant 
outcome 
1 
Moroti et al. 
Lipids 
Health Dis. 
2012 Brazil 10 10 F 50-60 T2DM 
4 
weeks 
Synbiotic 
200 mL of a symbiotic 
shake containing 108 
UFC/mL Lactobacillus 
acidophilus, 108 UFC/mL 
Bifidobacterium bifidum 
and 2 g 
oligofructose/placebo:20
0 ml of shake without 
synbiotic 
Increase in HDL-
c, reduction in 
fasting glycemia 
2 
Pourghassem 
et al. 
Compleme
ntary 
Therapies 
in Medicine 
2013 Iran 24 25 F 20-65 T2DM 8weeks Prebiotic 
10 g/day of inulin/ 
maltodextrin(placebo) 
Reduction in 
FPG, HbA1c and 
MDA; increase in 
total antioxidant 
capacity and 
superoxide 
dismutase 
activity 
5 
Pourghassem 
et al. 
Compleme
ntary 
Therapies 
in Medicine 
2015 Iran 28 32 F 30-65 T2DM 
8 
weeks 
Prebiotic 
10g/d Resistant Starch 
(RS2)[2 packages of 5 g] 
Reduction in 
HbA1c, TNF-α, 
triglyceride, 
increase in HDL-c 
4 
Shakeri et al. Lipids 2014 Iran 26 26 F/M 35–70 T2DM 
8 
weeks 
Synbiotic 
40 g package of synbiotic 
bread or probiotic bread 
for a total of 120 g/day 
Reduction in 
serum TAG, 
VLDL-C, TC/HDL-
C; increase in 
HDL-c 
5 
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Figure 2. Forest plot showing the association between prebiotic/synbiotics and serum TG(A), TC(B), LDL-C(C), HDL-C(D), FBG(E), 
HbA1c(F). Abbreviations: TG, triglyceride; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density 
lipoprotein cholesterol; FBG, fasting blood glucose; d. Random effects model was used to pool the mean change of indicators. 
 
 
 
Figure 3. Funnel plot of studies included in the meta-analysis for the outcome of HDL (A) and LDL (B). RR = Relative Risk, SE = 
standard error. HDL= High Density Lipoprotein, LDL= Low Density Lipoprotein 
 
Subgroup analysis 
As there is a significant heterogeneity among studies, we 
decided to explore the source of heterogeneity by 
subgroup analysis. Thus, we performed the analyses 
based on intervention (prebiotic or synbiotic) and study 
quality (high quality or low quality studies) (Table 2).  
When analyzed based on intervention, TG, LDL and 
HDL showed a significant difference in synbiotic group 
compared with placebo (TG WMD = -44.94, 95% CI -
80.96 to -8.92; LDL WMD = 4.8, 95% CI 2.77 to 6.84; 
HDL WMD = 4.94, 95% CI 4.05 to 5.83). In regard to 
second type of intervention, prebiotic group had 
significant decrease in TG (WMD= -31.29, 95%CI -
49.85 to -12.73), TC (WMD= -15.01, 95%CI -27.44 to -
2.58), FBG ( WMD= -12.40, 95%CI -15.86 to -8.94) and 
HbA1c (WMD=-0.47, 95%CI -0.8 to -0.13), marginally 
significant decrease in LDL (WMD= -20.78, 95%CI -
43.96 to 2.40) and significant increase in HDL (WMD= 
4.75, 95%CI 3.39 to 6.12)(Table 2). Another subgroup 
analysis was performed considering study quality. In 
high quality studies, TG, TC, FBG and HbA1c were 
decreased significantly in intervention group in 
comparison with control group (WMD=-37, 95%CI -
51.82 to -22.19 for TG, WMD= -13.17, 95%CI -21.42 to 
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-4.93 for TC; WMD=- 13.66, 95% CI -15.94 to -11.39 
for FBG; WMD= -0.55, 95%CI -0.76 to -0.33 for 
HbA1c). Moreover in this subgroup, HDL showed a 
significant increase in intervention group compared with 
placebo (WMD= 5.41, 95% CI 3.91 to 6.92). Low 
quality studies showed significant increase in HDL 
(WMD= 4.72, 95%CI 3.86 to 5.58) and LDL (WMD= 
5.09, 95%CI 3.08 to 7.11) while other factors had non-
significant changes in this subgroup (Table 2).  
 
Table 2. Subgroup analysis* 
Subgroup 
 
TG 
 
TC 
 
LDL  
  
WMD 
(95% CI) 
Test for 
heterogene
ity (I2, P) 
overall 
effect 
(P value) 
WMD 
(95% CI) 
Test for 
heterogeneity 
(I2, P) 
overall 
effect 
(P value) 
WMD 
(95% CI) 
Test for 
heterogeneity 
(I2, P) 
overall 
effect 
(P value) 
Intervention 
Synbiotic 
-44.94 [-80.96, 
-8.92] 
59%, 
p=0.09 
p=0.01 
-6.18 [-26.11, 
13.75] 
87%, 
p<0.0001 
p=0.54 
4.80 [2.77, 
6.84] 
0%, p=0.5 p<0.001 
Prebiotic 
-31.29 [-49.85, 
-12.73] 
47%, 
p=0.11 
p=0.001 
-15.01 [-
27.44, -2.58] 
33%, p=0.20 p=0.02 
-20.78 [-43.96, 
2.40] 
88%, p<0.001 p=0.08 
Quality of 
Study 
Low 
Quality 
-11.26 [-49.43, 
26.90] 
97%, 
p<0.001 
p=0.56 
-3.59 [-31.65, 
24.46] 
84%, p=0.002 p=0.8 
5.09 [3.08, 
7.11] 
0%, p=0.99 p<0.001 
High 
Quality 
-37.00 [-51.82, 
-22.19] 
6%, p=0.38 p<0.001 
-13.17 [-
21.42, -4.93] 
6%, p=0.38 p=0.002 
-18.06 [-35.40, 
-0.71] 
81%, 
p=0.0001 
p=0.04 
Subgroup 
 
HDL 
 
FBG 
 
HbA1c  
  
WMD (95% CI) 
Test for 
heterogene
ity (I2, P) 
overall 
effect 
(P value) 
WMD 
(95% CI) 
Test for 
heterogeneity 
(I2, P) 
overall 
effect 
(P value) 
WMD (95% CI) 
Test for 
heterogeneity 
(I2, P) 
overall 
effect 
(P value) 
Intervention 
Synbiotic 
4.94 [4.05, 
5.83] 
26%, 
p=0.26 
p<0.0001 
-3.33 [-56.83, 
30.16] 
99%, p<0.001 P=0.55 Not applicable 
Not 
applicable 
Not 
applicable 
Prebiotic 
4.75 [3.39, 
6.12] 
64%, 
p=0.03 
p<0.0001 
-12.40 [-
15.86, -8.94] 
68%, p=0.009 p<0.0001 
-0.47 [-0.8, -
0.13] 
92%, p<0.001 p<0.0001 
Quality of 
study 
Low 
Quality 
4.72 [3.86, 
5.58] 
62%, 
p=0.07 
p<0.001 
-12.95 [-
45.79, 19.89] 
99%, p<0.001 p=0.44 Not applicable 
Not 
applicable 
Not 
applicable 
High 
Quality 
5.41 
[3.91,6.92] 
46%, p=0.1 p<0.001 
-13.66 [-
15.94, -11.39] 
27%, p=0.21 p<0.001 
-0.55 [-0.76, -
0.33] 
90%, p<0.001 p<0.001 
*: Abbreviations: TG, triglycerides; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein 
cholesterol;; FBG, fasting blood glucose; WMD, weighted mean difference; CI, confidence interval. 
 
The heterogeneity was decreased significantly after 
subgroup analysis especially for study quality subgroup. 
In subgroup analysis based on intervention, the prebiotic 
and synbiotic group showed no significant heterogeneity 
across the trials in regard to TG/cholesterol and 
TG/LDL/HDL respectively (Table 2). On the other hand, 
subgroup analysis by study quality, showed the most 
reductive effect on heterogeneity. It has been shown that 
except for LDL and HbA1c, there is no significant 
heterogeneity across the trials in regard to other factors 
(Table 2).  
Vulevic et al reported that a galactooligosaccharide 
mixture could reduce markers of metabolic syndrome 
and modulate immune function in overweight adults.34 A 
pilot study demonstrated that prebiotic consumption 
might beneficially affect insulin level, with no significant 
effects on plasma lipids, in patients with non-alcoholic 
steatohepatitis.35 Eslamparast and her colleagues reported 
that synbiotic supplement can help in the management of 
metabolic syndrome and insulin resistance.36 Two other 
studies also suggested protective effects of prebiotics in 
patients with prediabetes.13,37 Published meta-analyses in 
this area are limited in number.  
A recent meta-analysis has been conducted on the effects 
of prebiotics on glycaemia, insulin concentrations and 
lipid parameters in overweight and obese adults and the 
results showed positive effects of prebiotics and 
synbiotics on dyslipidemia and insulin resistance.32 
Another systematic review was conducted to evaluate 
metabolic benefits of prebiotics in human subjects. The 
results indicated that prebiotic consumption is associated 
with improved self- reported feelings of satiety along 
with reduced postprandial glucose and insulin 
concentrations.38 To the best of our knowledge, the 
present study is first to systematically evaluate effects of 
prebiotic consumption on glycaemia and lipid profile in 
T2DM patients. In the present study, a significant 
heterogeneity was found among individual studies for 
target indicators (except for HDL-c).Two subgroup 
analyses were conducted based on intervention type 
(prebiotic or synbiotic), and study quality (high quality 
vs. low quality studies).  
After the subgroup analysis by intervention, the prebiotic 
subgroup showed no heterogeneity in TG and TC 
significantly. The heterogeneity in TG, LDL and HDL 
has been removed after the subgroup analysis based on 
the synbiotic intervention. Anyway, the quality of studies 
was shown as the most important source of 
heterogeneity. The heterogeneity of all outcomes, except 
for LDL and HbA1C, was removed after the subgroup 
analysis of seven high quality studies.16,22-25,27,31 Thus, we 
can assume that the source of heterogeneity is partially 
related to quality of the studies. 
Based on intervention, synbiotic consumption led to 
significant improvements in TG, HDL-c, and LDL-c 
concentrations. Other intervention, prebiotic, 
significantly improved TC, TG, FBG, and HbA1c.  
When analyzed by study quality, high quality studies 
showed beneficial effects of prebiotic/synbiotics on 
factors of glycaemia and lipid markers (except for LDL-
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c), while in low quality studies, intervention group had 
only significant improvements in HDL-c.  
There are controversial results on the efficacy of 
prebiotics/synbiotics in improvements of lipid profile 
and glycemic index. Increasing enteroendocrine cell 
activity, improved glucose homeostasis and modulated 
gut microbiota by intake of prebiotics, especially FOS, 
have been shown via prior studies.39,40 On the other hand, 
some studies could not find these favorable effects of 
prebiotics; they showed no significant effects on 
glycemic and lipid indices, especially lipid profiles, in 
diabetic participants.41,42 These controversial findings, 
and of course, the significant heterogeneity reported for 
our included studies, might be a result of different 
probiotic strains and prebiotic types, administration 
dosage, clinical characteristics of participants, duration 
of intervention, or lack of appropriate controls or 
placebo.43 
Our study is supportive of the idea that 
prebiotic/synbiotic consumption contribute to positive 
effects on blood lipid fractions; several mechanisms are 
proposed explaining this relationship. Inulin- type 
fructans reduce the denovo synthesis of fatty acids in the 
liver, thus result in decreased levels of serum or liver 
TG.44 The bacterial fermentation of non-digestible 
oligosaccharides (NDOs) in GI tract, leads to the 
formation of short chain fatty acids (SCFAs) including 
propionate, butyrate and acetate with different ratios 
depending on the substrate type.45 3-hydroxy-3-glutaryl-
Co-A (HMG CoA) reductase, is a key enzyme in 
cholesterol synthesis; by inhibiting its activity, 
propionate might play a role in serum cholesterol 
reduction.46 Probiotics can also reduce intestinal 
cholesterol absorption accompanied by its increased 
fecal excretion.43  
In this meta-analysis prebiotic/synbiotics showed 
promising effects in glucose homeostasis. Studies have 
explained the underlying mechanisms: soluble fibers can 
delay gastric emptying, retard entry of glucose into blood 
stream, and decrease the postprandial rise of serum 
glucose. In addition, soluble fibers modify the secretion 
of GLP-1 that is a gut hormone engaged in glucose 
metabolism; they also lead to SCFA production and 
therefore may affect serum glucose and insulin levels.27 
On the whole, probiotics and prebiotics are safe 
products. However, high doses of prebiotics increase the 
risk of bloating, flatulence and GI discomfort which 
might widely vary from person to person depending on 
the type of food.47 
Our study encounters some basic limitations. Using Q 
statistics and I2, the included studies showed significant 
heterogeneity. Subgroup analyses were conducted to 
detect the source of heterogeneity. However, such 
heterogeneity still remained in most subgroups, except 
for quality of studies. One limitation of the meta-analysis 
is that some of the studies included in the meta-analysis 
are not independent. Seven studies of ten studies are 
from the same country (Iran). They are different 
publications, but the data seem to originate from the 
same groups of subjects. Another limitation of the 
present meta-analysis is the fact that there are no 
included trials with T1DM patients. Therefore, the 
findings and their interpretations are limited to T2DM 
patients. 
Clinical heterogeneity between studies can lead to 
statistical heterogeneity in their results. In addition, this 
meta-analysis indicated possible publication bias in LDL 
but not in HDL. It is maybe because we included the 
studies, which were conducted with the same population 
(country and geographical region). 
Publication bias has been reported in several large meta-
analyses published in major medical journals; significant 
and positive results are more probable to be published 
and this is the main reason for such reported bias. Our 
meta-analysis included some methodologically low 
quality studies, which is another key source of bias. 
Since smaller studies need larger treatment effects to be 
published, they are more prone to such noted biases. 
In subgroup analyses conducted based on study quality, 
stronger beneficial effects were found in treatment group 
in comparison with control one. Based on this finding, 
we can conclude that either heterogeneity or true 
treatment effect could be the cause of publication bias.  
 
Conclusion  
Conclusively, our meta-analysis found that diets 
supplemented with either prebiotics or synbiotics can 
result in improvements in lipid metabolism and glucose 
homeostasis in patients with T2DM. Even though the 
overall analysis did not show significant changes for TC 
and LDL-c, subgroup analyses could find more 
noticeable changes in these markers. 
Considering the limitations for individual trials, 
prebiotics/synbiotics cannot be prescribed as alternative 
medicine T2DM, but these patients might benefit from 
these components as a complementary advise besides 
medicine and lifestyle modifications. 
More research are suggested with larger sample sizes, to 
determine the effective and also safe dose, duration and 
the best combinations of probiotics and prebiotics to 
reach a maximum positive effect. 
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